Shield Therapeutics (STX) Competitors GBX 3.43 -0.22 (-5.95%) As of 10:24 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock STX vs. ELX, TAO, APC, DGI, IDEA, VLG, DNL, EAH, PXS, and CHLLShould you be buying Shield Therapeutics stock or one of its competitors? The main competitors of Shield Therapeutics include El Oro (ELX), TAO Alpha (TAO), Apc Technology Group (APC), DG Innovate (DGI), Ideagen (IDEA), Venture Life Group (VLG), Diurnal Group (DNL), ECO Animal Health Group (EAH), Provexis (PXS), and Chill Brands Group (CHLL). Shield Therapeutics vs. Its Competitors El Oro TAO Alpha Apc Technology Group DG Innovate Ideagen Venture Life Group Diurnal Group ECO Animal Health Group Provexis Chill Brands Group Shield Therapeutics (LON:STX) and El Oro (LON:ELX) are both small-cap computer hardware companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk. Is STX or ELX more profitable? El Oro has a net margin of 0.00% compared to Shield Therapeutics' net margin of -173.43%. El Oro's return on equity of 0.00% beat Shield Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Shield Therapeutics-173.43% -470.50% -47.85% El Oro N/A N/A N/A Does the media refer more to STX or ELX? In the previous week, Shield Therapeutics had 1 more articles in the media than El Oro. MarketBeat recorded 1 mentions for Shield Therapeutics and 0 mentions for El Oro. Shield Therapeutics' average media sentiment score of 0.00 equaled El Oro'saverage media sentiment score. Company Overall Sentiment Shield Therapeutics Neutral El Oro Neutral Which has stronger valuation & earnings, STX or ELX? El Oro has lower revenue, but higher earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than El Oro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioShield Therapeutics£20.92M1.62-£36.28M-£3.88-0.88El Oro-£7.25M0.00N/A-£2.50N/A Do insiders and institutionals hold more shares of STX or ELX? 11.9% of Shield Therapeutics shares are owned by institutional investors. 62.2% of Shield Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryShield Therapeutics beats El Oro on 5 of the 9 factors compared between the two stocks. Get Shield Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STX vs. The Competition Export to ExcelMetricShield TherapeuticsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£33.88M£2.16B£5.50B£3.01BDividend YieldN/A2.92%4.25%5.02%P/E Ratio-0.884.1528.10165.92Price / Sales1.62577.05402.28320,986.79Price / Cash6.3610.3535.5327.97Price / Book62.7311.248.264.56Net Income-£36.28M£21.15B£3.24B£5.90B7 Day Performance19.20%0.18%0.50%6.83%1 Month Performance38.43%4.36%7.99%13.91%1 Year Performance114.56%3.03%28.68%72.70% Shield Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STXShield TherapeuticsN/AGBX 3.43-5.9%N/A+135.2%£33.88M£20.92M-0.8840,000News CoverageGap DownELXEl OroN/AN/AN/AN/A£41.06M-£7.25M-26.001,122TAOTAO AlphaN/AGBX 7.10+31.5%N/AN/A£26.89MN/A-32.503Gap UpHigh Trading VolumeAPCApc Technology GroupN/AN/AN/AN/A£18.03M£19.20M19.75164,000News CoverageDGIDG InnovateN/AN/AN/AN/A£1.90M£24.50K-1.25790Gap DownIDEAIdeagenN/AN/AN/AN/A£1.03B£75.28M17,450.009VLGVenture Life GroupN/AGBX 58.55-0.8%N/A+16.1%£74.61M£51.77M99.36165Positive NewsDNLDiurnal GroupN/AN/AN/AN/A£46.33M£4.68M-3.2133EAHECO Animal Health Group3.4899 of 5 starsGBX 59.94-0.1%N/A-38.1%£40.62M£89.44M38.75234News CoverageEarnings ReportAnalyst ForecastInsider TradeGap DownPXSProvexisN/AGBX 0.76-6.0%N/A+24.4%£17.72M£846.98K-28.624Gap DownCHLLChill Brands GroupN/AN/AN/AN/A£10.89M£624.19K-215.007Earnings Report Related Companies and Tools Related Companies ELX Competitors TAO Competitors APC Competitors DGI Competitors IDEA Competitors VLG Competitors DNL Competitors EAH Competitors PXS Competitors CHLL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:STX) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shield Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Shield Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
